Get started
Author

Arnaud Boyer

Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
2021 · Vincent Dubée, Pierre-Marie Roy, et al. · Clinical Microbiology and Infection · 46
PDF
Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer
2019 · M. Bilous, C. Serdjebi, et al. · Scientific Reports · 43
PDF
Effect of Prone Positioning on the Respiratory Support of Nonintubated Patients With COVID-19 and Acute Hypoxemic Respiratory Failure
2021 · Eloi Prud’homme, Youssef Trigui, et al. · CHEST Journal · 36
PDF
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
2018 · Arnaud Boyer, Eddy Pasquier, et al. · European Respiratory Review · 26
PDF
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study
2023 · Lionel Falchero, Florian Guisier, et al. · Lung Cancer · 25
PDF
Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer
2018 · Pascale Tomasini, Laurent Greillier, et al. · Journal of Thoracic Disease · 23
Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non‐Small Cell Lung Carcinoma
2017 · Diane‐Charlotte Imbs, Raouf El Cheikh, et al. · CPT Pharmacometrics & Systems Pharmacology · 21
PDF
Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
2019 · Benjamin K. Schneider, Arnaud Boyer, et al. · CPT Pharmacometrics & Systems Pharmacology · 13
PDF
LBA65 Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: Interim analysis (IA) of the phase II MDT-BRIDGE study
2025 · M. Reck, N. Girard, et al. · Annals of Oncology · 10
PDF
Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer
2018 · Arnaud Jeanson, Arnaud Boyer, et al. · Expert Review of Anticancer Therapy · 9
Évaluation par tomodensitométrie thoracique d’un traitement de la trachéobronchomalacie par pression positive continue dans le cadre d’un syndrome de Mounier–Kuhn
2020 · J. Bismuth, P. Habert, et al. · Revue des Maladies Respiratoires · 3
1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial
2024 · J. Ciccolini, M. Hamimed, et al. · Annals of Oncology · 2
PDF
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
2023 · Lionel Falchero, Florian Guisier, et al. · Journal of Clinical Oncology · 2
Abstract LB120: Comprehensive biomarkers analysis to explain resistances to PD1-L1 ICIs: The precision immuno-oncology for advanced non-small cell lung cancer (PIONeeR) trial
2022 · Laurent Greillier, Florence Monville, et al. · Cancer Research · 1
Ipilimumab et cancer bronchique métastatique : peut-on changer l’histoire naturelle de la maladie ?
2015 · A. Boyer, L. Greillier, et al. · Revue des Maladies Respiratoires · 1
Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial
2026 · Martin Reck, Ernest Nadal, et al. · Nature Medicine
PDF
Chemoradiotherapy (CRT) Followed By Consolidation Durvalumab (D) In Patients (pts) with Resectable or Borderline Resectable Stage IIB–IIIB NSCLC Who Become Unresectable during Neoadjuvant Treatment (Tx): Results from the Phase 2 MDT-Bridge Study
2026 · A.R. Filippi, M. Reck, et al. · International Journal of Radiation Oncology*Biology*Physics
A80-2-15 Lung Cancer Screening in a French Hospital by Low-Dose CT Scan Using Screening Kiosks. Results of the Depitab Study After Two Rounds
2026 · A Boyer, A Palot, et al. · American Journal of Respiratory and Critical Care Medicine
782-C Regulatory T-cell tumor infiltration is associated to better outcome in advanced NSCLC patients under ≥2ndline anti-PD1/L1 monotherapy in the PIONeeR project
2023 · Marcellin Landri, Margot Vasseur, et al. · Journal for ImmunoTherapy of Cancer
PDF
701 Brightplex® TCE and brightplex® MDSC assays combination improves advanced NSCLC patients’ stratification under anti-PD1/L1 immunotherapy in the PIONeeR project
2022 · Lamia Ghezali, Marcellin Landri, et al. · Journal for ImmunoTherapy of Cancer
PDF
460 Spatial distribution of infiltrating T lymphocytes with Immunoscore® CR T cells exhaustion test helps stratification of NSCLC patients treated with PD1/PDL1 inhibitors in the PIONeeR project
2021 · Vanina Leca, Alboukadel Kassambara, et al. · Journal for ImmunoTherapy of Cancer
PDF
Effet du décubitus ventral vigile sur l’augmentation du support ventilatoire des patients atteints d’une pneumonie hypoxémiante à COVID-19 : étude de cohorte rétrospective
2021 · E. Prud’homme, Y. Trigui, et al. · Revue des Maladies Respiratoires Actualités
Cáncer de pulmón primario
2019 · A. Boyer, P. Tomasini, et al. · EMC - Tratado de Medicina
Modeling Primary Tumor Dynamics of Human-to-Mouse Xenografted Non-Small Cell Lung Cancer in Response to Administration of Bevacizumab and Pemetrexed-Cisplatin
2018 · Schneider, Benjamin, Boyer, Arnaud, et al. · HAL AMU
Abstract 4529: Optimization of the sequence for the administration of bevacizumab in combination with pemetrexed and cisplatin in NSCLC : a pharmacology based in vivo study
2017 · arnaud boyer, diane-charlotte imbs, et al. · Cancer Research
Works count: 26
Citation count: 261
H-index: 9
I10-index: 9
Year
Topic
Type